(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2013 (27.12.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/192550 A2

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/US2013/047109

(22) International Filing Date:
21 June 2013 (21.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/663,307	22 June 2012 (22.06.2012)	US
61/749,212	4 January 2013 (04.01.2013)	US
61/749,486	7 January 2013 (07.01.2013)	US
61/755,810	23 January 2013 (23.01.2013)	US

(71) Applicant: **CYTOMX THERAPEUTICS, INC.** [US/US]; 650 Gateway Boulevard #125, South San Francisco, CA 94080-7014 (US).

(72) Inventors: **WEST, James, William**; 724 Laurel Avenue, Apt. 404, San Mateo, CA 94401 (US). **SAGERT, Jason, Gary**; 231 Laurie Meadows Road, Apt. 153, San Mateo, CA 94403 (US). **BESSETTE, Paul, H.**; 441 Avocado Place, Camarillo, CA 93010 (US). **LOWMAN, Henry, Bernard**; P.O. Box 2556, El Granada, CA 94018-2556 (US). **STAGLIANO, Nancy, E.**; 851 Indiana Street, Unit 503, San Francisco, CA 94107 (US). **VASILJEVA, Olga**; 20080 Rodrigues Avenue # D, Cupertino, 95104 (US). **MENENDEZ, Elizabeth-Edna, Mary**; 2235 Southampton Way, San Mateo, CA 94403 (US).

(74) Agents: **ELRIFI, Ivor, R.** et al.; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF




FIGURE 1

(57) Abstract: This invention relates generally to the generation of antibodies, *e.g.*, monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, *e.g.*, monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, *e.g.*, nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti- Jagged antibodies and methods of using the anti- Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti- Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

WO 2013/192550 A2